



Buoyant increase in revenue in 2011: +42.5% to €6.94m

Paris, 27 February 2012 – EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announces its consolidated revenue for the financial year to 31 December 2011.

Consolidated revenue by activity

<i>In millions of euros</i>	31 Dec. 2011	31 Dec. 2010	Δ %
Equipment sales	6.30	4.32	+45.8%
<i>% of total revenue</i>	<i>90.8%</i>	<i>88.7%</i>	
Service sales	0.64	0.55	+16.7%
<i>% of total revenue</i>	<i>9.25%</i>	<i>11.3%</i>	
Total revenue	6.94	4.87	+42.5%

Non audited accounts

As announced at the time of the presentation of its IPO project, EOS imaging recorded consolidated annual revenue of €6.94m in 2011, up +42.5% compared to the previous financial year.

Equipment sales recorded a buoyant increase of +45.8% compared to 2010, totaling €6.30m and accounting for 90.8% of total Group revenue. Over 2011, the Group sold 16 EOS[®] platforms.

Sales of services, which essentially consist of maintenance contracts, totaled €0.64m over the year. Up +16.7% compared to 2010, they accounted for 9.25% of total Group revenue in 2011.

Consolidated revenue by geographical zone

<i>In millions of euros</i>	31 Dec. 2011	31 Dec. 2010	Δ %
Europe	3.92	2.56	+53.0%
North America	2.02	1.91	+5.54%
Rest of the World	1.01	0.40	+152%
Total revenue	6.94	4.87	+42.5%

Non audited accounts

EOS imaging recorded revenue of €3.10m in France, a jump of +125%, which thus accounted for 44.6% of total 2011 Group revenue.

Revenue from abroad totaled €3.85m in 2011, an increase of 10.1%, which thus accounted for 55.4% of total revenue.



▪ **2012, pursuance of the growth strategy**

Thanks to the 38 million euros raised by the Group's IPO on the NYSE Euronext Paris, EOS imaging possesses the financial means to accelerate its proactive sales deployment, and to broaden its innovative service offering.

Marie Meynadier, CEO of EOS imaging, says: *"The buoyant increase in activity recorded in 2011 reflects the very positive momentum initiated by our sales teams. This early part of the year also saw the success of our IPO, which will enable us to expand our sales force and to build a conquering sales organization around the world. I would like to make the most of this first financial publication to thank the shareholders who have come onboard and who will thus help make EOS imaging the global leader in osteoarticular imaging."*

About EOS imaging:

The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EC). Thanks to an installed base of 42 sites and more than 150,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group recorded annual revenue of 6.94 million euros in 2011, and at 31 December 2011 employed 57 people including an R&D team of 21 engineers. The Group's head office is based in Paris, with a subsidiary in the United States at Cambridge, Massachusetts, as well as offices in Montreal (Canada) and Germany.

For further information, go to www.eos-imaging.com

**EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI**



Contacts :

Anne Renevot
CFO
Tel.: +33 (0)1 55 25 61 24
investors@eos-imaging.com

NewCap.
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33(0)1 44 71 94 91 – eosimaging@newcap.fr

ALIZE RP
Press Relations
Caroline Carmagnol / Anne-Sophie Cosquéric
Tel : +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59
caroline@alizerp.com / anne-sophie@alizerp.com